

# Allogeneic UCB-derived CAR-T for SLE

NCT07274059

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Early Phase 1
<b>Sponsor</b>	Chengdu Ucello Biotechnology Co., Ltd.
<b>Enrollment</b>	48 participants

## Key Eligibility Criteria

---

### Inclusion (12)

- Aged 18 to 75 years (inclusive), regardless of gender.
- Definitive diagnosis of systemic lupus erythematosus (SLE) meeting the 2019 European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) classification criteria for SLE
- Treatment refractory: failed 2 conventional SLE treatments for at least 3 months.
- Disease activity assessed by SELENA-SLEDAI score  $\geq 6$  with at least one British Isles Lupus Assessment Group (BILAG)-2004 Class A (severe manifestation) or two Class B (moderate manifestation) organ scores (or both); OR SELENA-SLEDAI score  $\geq 8$ .
- Adequate function of major organs as follows:  
... and 7 more (see full listing online)

### Exclusion (11)

- History of severe drug allergies or atopic diathesis.
- Presence or suspicion of uncontrolled or treatment-requiring fungal, bacterial, viral, or other infections.
- Cardiac function insufficient to tolerate the study treatment.
- Congenital immunoglobulin deficiency.
- History of malignant tumors within the past 5 years.  
... and 6 more (see full listing online)

## Locations (2 total)

---

Yancheng Third People's Hospital, Yancheng, Jiangsu, China  
The General Hospital of Western Theater Command, Chengdu, Sichuan, China